To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials.
To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials.
复制标题
DOI：
10.1016/j.jve.2023.100339
复制
发表时间：
2023-09
影响因子：
5.5
通讯作者：
Dube, Karine
中科院分区：
文献类型：
--
作者：
Patel, Hursch;Dube, Karine
广泛中和抗体（bNAbs）作为人类免疫缺陷病毒（HIV）的治疗相关研究策略已引起科学界的关注。bNAbs是一种专门针对HIV-1的抗体，通过与病毒表面的蛋白质结合，阻止人类细胞的感染。在评估bNAb使用的HIV-1临床研究中，对潜在参与者进行bNAb敏感性的预筛选是一种常见的做法。然而，在HIV-1 bNAb临床试验中使用预筛查是一个持续争论的话题，涉及其潜在的益处和局限性。在本文中，我们研究了在HIV-1治疗相关研究中预先筛选bNAb敏感性的可能益处和局限性，并提出了在节省成本和时间方面可能更有效或更有效的替代方法。最终，在HIV-1 bNAb临床试验中使用预筛查的决定应该基于对该方法的潜在益处和局限性的仔细评估，以及研究的具体需求、目标、设计和人群。
The use of broadly neutralizing antibodies (bNAbs) as a cure-related research strategy for human immunodeficiency virus (HIV) has gained attention from the scientific community. bNAbs are specialized antibodies that target HIV-1 by binding to proteins on the surface of the virus, preventing the infection of human cells. In HIV-1 clinical studies assessing the use of bNAbs, it has been common practice to prescreen potential participants for bNAb sensitivity. However, the use of pre-screening in HIV-1 bNAb clinical trials is a topic of ongoing debate, with regard to its potential benefits and limitations. In this paper, we examine the possible benefits and limitations of pre-screening for bNAb sensitivity in HIV-1 cure-related studies, and suggest alternative methods which may be more effective or efficient at saving costs and time. Ultimately, the decision to use pre-screening in HIV-1 bNAb clinical trials should be based on a careful assessment of the potential benefits and limitations of this approach, as well as the specific needs, goals, design, and population of the study in question.
登录
查看更多内容
影响因子：
82.9
作者：
Julg, Boris;Stephenson, Kathryn E.;Wagh, Kshitij;Tan, Sabrina C.;Zash, Rebecca;Walsh, Stephen;Ansel, Jessica;Kanjilal, Diane;Nkolola, Joseph;Walker-Sperling, Victoria E. K.;Ophel, Jasper;Yanosick, Katherine;Borducchi, Erica N.;Maxfield, Lori;Abbink, Peter;Peter, Lauren;Yates, Nicole L.;Wesley, Martina S.;Hassell, Tom;Gelderblom, Huub C.;deCamp, Allen;Mayer, Bryan T.;Sato, Alicia;Gerber, Monica W.;Giorgi, Elena E.;Gama, Lucio;Koup, Richard A.;Mascola, John R.;Monczor, Ana;Lupo, Sofia;Rolle, Charlotte-Paige;Arduino, Roberto;DeJesus, Edwin;Tomaras, Georgia D.;Seaman, Michael S.;Korber, Bette;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
DOI：
10.1093/cid/ciq164
发表时间：
2011-02-15
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Kouyos RD;von Wyl V;Yerly S;Böni J;Rieder P;Joos B;Taffé P;Shah C;Bürgisser P;Klimkait T;Weber R;Hirschel B;Cavassini M;Rauch A;Battegay M;Vernazza PL;Bernasconi E;Ledergerber B;Bonhoeffer S;Günthard HF;Swiss HIV Cohort Study
通讯作者：
Swiss HIV Cohort Study
影响因子：
3.7
作者：
O'Rourke SM;Sutthent R;Phung P;Mesa KA;Frigon NL;To B;Horthongkham N;Limoli K;Wrin T;Berman PW
通讯作者：
Berman PW
DOI：
10.1097/qad.0000000000000106
发表时间：
2014-01-14
期刊：
AIDS (London, England)
影响因子：
--
作者：
Hraber P;Seaman MS;Bailer RT;Mascola JR;Montefiori DC;Korber BT
通讯作者：
Korber BT
影响因子：
3.7
作者：
Makhdoomi, Muzamil Ashraf;Singh, Deepti;Luthra, Kalpana
通讯作者：
Luthra, Kalpana